1 week Ago
Olivier Le Moal This is my second Crinetics Pharmaceuticals ( NASDAQ: CRNX ) article, coming after 08/2024's "Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech" (" Listen "). I opened my Conclusion to Listen with the following: ..
.I consider Crinetics to be substantially Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ANY COMPANY MENTIONED over the next 72 hours. I wrote this article myself, and it expresses my own opinions.
I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results.
No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body..
